

Tomoya Yokota

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1114151/publications.pdf>

Version: 2024-02-01

97
papers

3,320
citations

279798

23
h-index

161849

54
g-index

98
all docs

98
docs citations

98
times ranked

4647
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic therapy for salivary gland malignancy: current status and future perspectives. Japanese Journal of Clinical Oncology, 2022, 52, 293-302.	1.3	12
2	Human papillomavirus-related oropharyngeal carcinoma. Japanese Journal of Clinical Oncology, 2022, 52, 700-706.	1.3	1
3	Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. International Journal of Clinical Oncology, 2021, 26, 494-506.	2.2	40
4	Defining the needs of patients with recurrent and/or metastatic head and neck cancer: An expert opinion. Critical Reviews in Oncology/Hematology, 2021, 157, 103200.	4.4	9
5	Real-world clinical outcomes and prognostic factors in Japanese patients with recurrent or metastatic squamous cell carcinoma of head and neck treated with chemotherapy plus cetuximab: a prospective observation study (JROSG12-2). International Journal of Clinical Oncology, 2021, 26, 316-325.	2.2	7
6	Triplet induction chemotherapy followed by less invasive surgery without reconstruction for human papillomavirus-associated oropharyngeal cancers: Why is it successful or unsuccessful?. International Journal of Clinical Oncology, 2021, 26, 1039-1048.	2.2	3
7	Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. Investigational New Drugs, 2021, 39, 1399-1404.	2.6	2
8	Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA. Esophagus, 2021, 18, 743-752.	1.9	8
9	Effectiveness of nivolumab affected by prior cetuximab use and neck dissection in Japanese patients with recurrent or metastatic head and neck cancer: results from a retrospective observational study in a real-world setting. International Journal of Clinical Oncology, 2021, 26, 1049-1056.	2.2	4
10	Incurable locoregional disease is a strong poor prognostic factor in recurrent or metastatic squamous cell carcinoma of the head and neck. International Journal of Clinical Oncology, 2021, 26, 1822-1830.	2.2	5
11	MO3-2 Prognostic significance of metastatic sites in recurrent or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology, 2021, 32, S296.	1.2	0
12	P1-2 Safety and efficacy of nivolumab therapy in patients with advanced esophageal squamous cell carcinoma. Annals of Oncology, 2021, 32, S328.	1.2	0
13	Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2021, 111, 794-803.	0.8	11
14	Efficacy and safety of 5-fluorouracil (5-FU) / levofolinate / irinotecan (FOLFIRI) for previously treated advanced pancreatic cancer (APC).. Journal of Clinical Oncology, 2021, 39, 407-407.	1.6	3
15	Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck. Japanese Journal of Clinical Oncology, 2021, 51, 173-179.	1.3	15
16	Pretreatment predictive factors for feasibility of oral intake in adjuvant concurrent chemoradiotherapy for patients with locally advanced squamous cell carcinoma of the head and neck. International Journal of Clinical Oncology, 2020, 25, 258-266.	2.2	4
17	A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Annals of Surgical Oncology, 2020, 27, 460-467.	1.5	29
18	ASO Author Reflections: How Should the Patients with Locally Advanced Unresectable Esophageal Cancer Be Treated with Multidisciplinary Approach?. Annals of Surgical Oncology, 2020, 27, 468-469.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Efficacy and feasibility of induction chemotherapy with paclitaxel, carboplatin and cetuximab for locally advanced unresectable head and neck cancer patients ineligible for combination treatment with docetaxel, cisplatin, and 5-fluorouracil. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1914-1920.	2.2	12
20	Immunotherapy for squamous cell carcinoma of the head and neck. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1089-1096.	1.3	39
21	How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?. <i>Current Oncology Reports</i> , 2020, 22, 118.	4.0	7
22	Rechallenge with Lenvatinib after Refractoriness to Initial Lenvatinib Followed by Sorafenib in a Patient with Metastatic Papillary Thyroid Carcinoma. <i>Case Reports in Oncology</i> , 2020, 13, 522-527.	0.7	10
23	Risk factors for aspiration pneumonia during concurrent chemoradiotherapy or bio-radiotherapy for head and neck cancer. <i>BMC Cancer</i> , 2020, 20, 182.	2.6	14
24	Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141). <i>Head and Neck</i> , 2020, 42, 2852-2862.	2.0	26
25	Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2020, 47, 650-657.	1.2	16
26	Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 972-977.	2.2	20
27	Chemoradiotherapy for high-risk stage II laryngeal cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1596-1603.	2.2	4
28	Comparison of doublet chemotherapy with monotherapy for vulnerable advanced colorectal cancer patients. <i>Journal of Clinical Oncology</i> , 2020, 38, 143-143.	1.6	0
29	Feasibility and efficacy of chemoradiotherapy with concurrent split-dose cisplatin after induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for locally advanced head and neck cancer. <i>Molecular and Clinical Oncology</i> , 2020, 13, 35.	1.0	4
30	Comparison of enteral nutrition with total parenteral nutrition for patients with locally advanced unresectable esophageal cancer harboring dysphagia in definitive chemoradiotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 910-918.	1.3	10
31	Preliminary Results of Safety and PK of Telisotuzumab Vedotin (T) in Japanese Patients with Advanced Solid Tumors. <i>Annals of Oncology</i> , 2019, 30, vi125.	1.2	1
32	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	13.7	1,804
33	A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 589-595.	1.3	19
34	Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck. <i>JAMA Oncology</i> , 2019, 5, 1170.	7.1	34
35	Is prophylactic percutaneous endoscopic gastrostomy necessary for chemoradiotherapy after total laryngectomy?. <i>Annals of Oncology</i> , 2019, 30, vi103.	1.2	0
36	Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. <i>International Journal of Clinical Oncology</i> , 2019, 24, 468-475.	2.2	19

#	ARTICLE	IF	CITATIONS
37	A prospective observation study of Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated by radiotherapy with cetuximab i¼JROSG12-2i¼%: interim appraisal of the safety and treatment compliance. Japanese Journal of Head and Neck Cancer, 2019, 45, 330-336.	0.1	0
38	Which treatment strategies are the most promising for locally advanced resectable human papillomavirus-associated oropharyngeal cancers?. Journal of Clinical Oncology, 2019, 37, e17556-e17556.	1.6	1
39	A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer. Supportive Care in Cancer, 2018, 26, 3241-3248.	2.2	13
40	Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer, 2018, 21, 338-344.	5.3	31
41	Concordance of clinical diagnosis of T classification among physicians for locally advanced unresectable thoracic esophageal cancer. International Journal of Clinical Oncology, 2018, 23, 73-80.	2.2	9
42	Medical oncology in multidisciplinary approach for head and neck cancer. Annals of Oncology, 2018, 29, vii22.	1.2	0
43	PS02.162: THREE-YEAR OVERALL SURVIVAL UPDATE FROM PHASE II STUDY OF CHEMOSELECTION WITH DCF AND SUBSEQUENT CONVERSION SURGERY FOR LOCALLY ADVANCED UNRESECTABLE ESOPHAGEAL CANCER. Ecological Management and Restoration, 2018, 31, 167-168.	0.4	0
44	Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial. BMC Cancer, 2018, 18, 873.	2.6	13
45	Phase II study of S-1 plus oxaliplatin 130Âmg/m2 in Japanese patients with advanced gastric cancer. International Journal of Clinical Oncology, 2018, 23, 1084-1089.	2.2	8
46	Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. BMC Cancer, 2018, 18, 573.	2.6	34
47	PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue. BMC Cancer, 2018, 18, 826.	2.6	11
48	Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. International Journal of Clinical Oncology, 2018, 23, 1189-1195.	2.2	7
49	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer, 2018, 118, 1571-1579.	6.4	2
50	Impact of the T and N stage in the American Joint Committee on Cancer (AJCC) 8th edition staging system for pancreatic cancer with curative resection.. Journal of Clinical Oncology, 2018, 36, 261-261.	1.6	0
51	Prognostic significance of nutritional risk index in patients with metastatic esophageal squamous cell cancer.. Journal of Clinical Oncology, 2018, 36, 156-156.	1.6	0
52	Impact of UGT1A1 gene polymorphism on survival in metastatic colorectal cancer patients treated with irinotecan-containing therapy.. Journal of Clinical Oncology, 2018, 36, 813-813.	1.6	0
53	Nutritional parameters for nutritional intervention as predictive factors in patients with metastatic esophageal squamous cell cancer.. Journal of Clinical Oncology, 2018, 36, e22185-e22185.	1.6	0
54	Prognostic impact of PIK3CA mutation in esophageal cancer: Molecular profiling by next-generation sequencing using formalin-fixed, paraffin-embedded tissues.. Journal of Clinical Oncology, 2018, 36, e16003-e16003.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2a-c. Japanese Journal of Clinical Oncology, 2017, 47, 705-712.	1.3	17
56	Gastrojejunostomy versus duodenal stent placement for gastric outlet obstruction in patients with unresectable pancreatic cancer. Pancreatology, 2017, 17, 983-989.	1.1	33
57	A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141. Oral Oncology, 2017, 73, 138-146.	1.5	90
58	Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer. Annals of Surgical Oncology, 2017, 24, 3741-3747.	1.5	44
59	Risk factors for aspiration pneumonia after definitive chemoradiotherapy or bio-radiotherapy for locally advanced head and neck cancer: a monocentric case control study. BMC Cancer, 2017, 17, 59.	2.6	31
60	Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer, 2017, 17, 314.	2.6	24
61	Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102. Clinical Colorectal Cancer, 2017, 16, 51-57.	2.3	42
62	Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clinical Colorectal Cancer, 2017, 16, e15-e22.	2.3	64
63	Safety and efficacy of chemoradiotherapy for high risk stage II laryngeal cancer. Annals of Oncology, 2017, 28, ix78.	1.2	0
64	Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with c-MET-amplified gastric cancer. Oncotarget, 2017, 8, 79546-79555.	1.8	21
65	Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer. Oncology, 2017, 93, 329-335.	1.9	14
66	A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan. Journal of Clinical Oncology, 2017, 35, 2536-2536.	1.6	3
67	LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal of Clinical Oncology, 2017, 35, 6001-6001.	1.6	12
68	Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status. Journal of Clinical Oncology, 2017, 35, 744-744.	1.6	1
69	Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months. Journal of Clinical Oncology, 2017, 35, 800-800.	1.6	2
70	Treatment course for unresectable locally advanced hypopharyngeal carcinoma. Japanese Journal of Head and Neck Cancer, 2017, 43, 33-38.	0.1	0
71	Phase II study of S-1 plus oxaliplatin (OX) at dose of 130 mg/m ² (SOX130) in Japanese patients (pts) with advanced gastric cancer (AGC). Journal of Clinical Oncology, 2017, 35, 112-112.	1.6	0
72	Role of surgery for gastric cancer with liver limited multiple metastases. Journal of Clinical Oncology, 2017, 35, 170-170.	1.6	0

#	ARTICLE	IF	CITATIONS
73	The impact of dose modification or termination of S-1 as adjuvant therapy on survival of locally advanced gastric cancer underwent curative gastrectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 193-193.	1.6	1
74	Is the new era of personalized medicine coming in head and neck cancer?. <i>Annals of Oncology</i> , 2016, 27, vii66.	1.2	0
75	A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 91-99.	2.3	49
76	Prognostic Factors and Multidisciplinary Postoperative Chemoradiotherapy for Clinical T4a Tongue Cancer. <i>Oncology</i> , 2016, 91, 78-84.	1.9	6
77	Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 809-814.	2.3	28
78	Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1000-1007.	1.3	6
79	Comparison of curative surgery and definitive chemoradiotherapy as initial treatment for patients with cervical esophageal cancer. <i>Ecological Management and Restoration</i> , 2016, 30, 1-5.	0.4	21
80	Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. <i>British Journal of Cancer</i> , 2016, 115, 1328-1334.	6.4	108
81	Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy. <i>Gastric Cancer</i> , 2016, 19, 894-901.	5.3	9
82	Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy. <i>Supportive Care in Cancer</i> , 2016, 24, 3029-36.	2.2	27
83	Accuracy of preoperative diagnosis of lymph node metastasis for thoracic esophageal cancer patients from JCOG9907. <i>International Journal of Clinical Oncology</i> , 2016, 21, 283-288.	2.2	25
84	Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6026-6026.	1.6	9
85	Efficacy and safety of irinotecan monotherapy as third line treatment for advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 113-113.	1.6	0
86	Phase II study of chemoselection with docetaxel plus 5-fluorouracil and cisplatin induction chemotherapy and subsequent conversion surgery for locally advanced unresectable esophageal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4021-4021.	1.6	0
87	Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases. <i>International Journal of Clinical Oncology</i> , 2015, 20, 455-462.	2.2	18
88	Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907). <i>Oncology</i> , 2015, 89, 143-151.	1.9	29
89	Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, hv142.	1.3	12
90	Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 183-188.	1.3	22

#	ARTICLE	IF	CITATIONS
91	Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. International Journal of Clinical Oncology, 2014, 19, 211-219.	2.2	21
92	Is postoperative adjuvant chemoradiotherapy necessary for high-risk oropharyngeal squamous cell carcinoma?. International Journal of Clinical Oncology, 2014, 19, 38-44.	2.2	12
93	Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 163-171.	1.7	113
94	S-1 Monotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck After Progression on Platinum-based Chemotherapy. Japanese Journal of Clinical Oncology, 2011, 41, 1351-1357.	1.3	12
95	Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer. Anticancer Research, 2011, 31, 3535-41.	1.1	44
96	Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. Translational Research, 2010, 156, 98-105.	5.0	27
97	<scp>Jâ€SUPPORT</scp> research policy for oral mucositis associated with cancer treatment. Cancer Medicine, 0, , .	2.8	2